Changes in the soluble mucosal immune environment during genital herpes outbreaks

J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):194-202. doi: 10.1097/QAI.0b013e31826867ae.

Abstract

Background: Genital tract secretions provide variable inhibitory activity against herpes simplex virus (HSV) ex vivo. We hypothesize that the anti-HSV activity may prevent the spread of virus from the more commonly affected sites, such as the external genitalia, to the upper genital tract.

Methods: The antimicrobial activity of cervicovaginal lavage (CVL) and concentrations of mucosal immune mediators were measured in 10 HIV-seronegative women with an active external herpetic lesion and compared with 10 HIV-seronegative women who were HSV-1 and HSV-2 seronegative. Samples were obtained at the time of a symptomatic external lesion (day 0), after 1 week of oral acyclovir (day 7), and 1 week after completing treatment (day 14). Controls were evaluated at parallel intervals.

Results: The anti-HSV activity was higher in CVL obtained from cases compared to controls at presentation (day 0) (54.3% vs. 28%), fell to similar levels on day 7, and then rebounded on day 14 (69% vs. 25%). The anti-HSV activity correlated positively and significantly with the concentrations of several inflammatory proteins; the concentrations of these proteins tended to be higher in cases compared with controls and followed a similar temporal pattern.

Conclusions: Increases in inflammatory immune mediators and anti-HSV activity were detected in CVL at the time of clinical outbreaks and after completion of a short course of acyclovir. These mucosal responses may protect against HSV spread but could facilitate HIV infection and contribute to the clinical observation that, independent of clinical lesions, HSV-2 is a risk factor for HIV acquisition.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Acyclovir / administration & dosage
  • Adolescent
  • Adult
  • Antiviral Agents / administration & dosage
  • Cervix Mucus / immunology*
  • Disease Outbreaks*
  • Female
  • Herpes Genitalis / drug therapy
  • Herpes Genitalis / epidemiology*
  • Herpes Genitalis / immunology*
  • Herpesvirus 1, Human / immunology*
  • Herpesvirus 2, Human / immunology*
  • Humans
  • Middle Aged
  • Vaginal Douching
  • Young Adult

Substances

  • Antiviral Agents
  • Acyclovir